The Management Team
We have a world class leadership team guiding us in our quest to develop the best medicines for our best friends.
Be part of the Transformation in veterinary medicine
We love the pets around us – our dogs, cats, and horses we share our lives with. Many of us believe these animals are part of the family, providing us unconditional love and companionship throughout our lives. We have an opportunity for cutting edge treatment when disease and chronic conditions cross our path, but what happens when our animal companions encounter these same issues?
Treatment options for our companion animals shouldn’t be limited
Download the Corporate Presentation to learn more about our strategy, team, and programs.
Read the Recent News from KindredBio.
Looking for More?
See Our Pipeline
KindredBio has an exciting pipeline of high-value products for dogs, cats, and horses in development.
$4.73 
-0.02 (-0.42%)
-0.02 (-0.42%)
|
||||||||||||||||
KindredBio proudly supports
Rabies Free Africa
Kindred Biosciences to Present at the BofA Securities Animal Health Virtual Summit
/in Frontpage, Investor, News /by Katja BuhrerSAN FRANCISCO, February 16, 2021 — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the BofA Securities Animal Health Virtual Summit on February 25. Dr. Richard Chin, Chief Executive Officer, will present via webcast at 10.50am ET and be available for virtual one-on-one meetings. During this […]
Kindred Biosciences Announces Two New Appointments to Board of Directors
/in Frontpage, Investor, News /by Katja BuhrerSan Francisco, California (February 9, 2021) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has appointed Lyndon Lien, Ph.D., an experienced biotech CEO, entrepreneur and investor, and Nanxi Liu, CEO and Co-Founder of Enplug and Co-Founder of Nanoly Bioscience, to its […]
Kindred Biosciences Initiates Pivotal Efficacy Study of Tirnovetmab (Interleukin-31) Monoclonal Antibody for Canine Atopic Dermatitis
/in Frontpage, Investor, News /by Katja BuhrerSan Francisco, California (December 22, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has initiated the pivotal efficacy study for tirnovetmab (KIND-016), a fully caninized, high-affinity monoclonal antibody targeting interleukin (IL)-31 for the treatment of atopic dermatitis in dogs. Atopic […]